NCT04852354 Tissue Collection for Drug Screening and Bioanalysis
| NCT ID | NCT04852354 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Weill Medical College of Cornell University |
| Condition | Central Nervous System Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2020-07-22 |
| Primary Completion | 2029-07-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2020-07-22 with a primary completion date of 2029-07-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to improve upon the knowledge currently available about central nervous system (CNS) tumors. We will study the different characteristics of these tumors using tissue samples collected during surgery and post-autopsy. The aim is to create tumor cell lines and models to test how they respond to different drugs. This research will help improve treatment options and identify new targets for therapy.
Eligibility Criteria
Inclusion Criteria for Tumor patients undergoing neurosurgery (cohort 1) 1. Subject has presented with a suspected/confirmed neoplastic CNS lesion and is undergoing a neurosurgical procedure in which CNS tissue and/or tumors associated with this tissue will be removed. 2. There must be tissue available in excess of that required by neuropathology for diagnostic purposes. 3. Subject of all ages included. 4. Subjects who are pregnant can be included. 5. Subjects who are neonates (0-4 weeks) can be included. Inclusion Criteria for Non-tumor patients undergoing neurosurgery (cohort 2) 1. Subject is between 4 weeks and 21 years of age and is undergoing a neurosurgical procedure at WCMC. 2. Subject does not have a CNS tumor diagnosis. 3. Subject should not be pregnant at the time of enrollment. Inclusion Criteria for Autopsy tumor tissue donation (cohort 3) 1. Subject of all ages included 2. Subject has been diagnosed with a neoplastic CNS lesion at the time of passing. 3. Subjects who are pregnant can be included. 4. Subjects who are neonates (0-4 weeks) can be included. Inclusion Criteria for parent of tumor patients 1. Subject is the biological parent of a patient undergoing/ who underwent a neurosurgical procedure in which CNS tissue and/or tumors associated with this tissue will be/ was removed. 2. Subject is the biological parent of patient enrolled in cohort 1. 3. Subject is not pregnant at the time of enrollment.
Contact & Investigator
Jeffrey Greenfield, M.D.
PRINCIPAL INVESTIGATOR
Weill Medical College of Cornell University
Frequently Asked Questions
Who can join the NCT04852354 clinical trial?
This trial is open to participants of all sexes, studying Central Nervous System Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04852354 currently recruiting?
Yes, NCT04852354 is actively recruiting participants. Contact the research team at jpgreenf@med.cornell.edu for enrollment information.
Where is the NCT04852354 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT04852354 clinical trial?
NCT04852354 is sponsored by Weill Medical College of Cornell University. The principal investigator is Jeffrey Greenfield, M.D. at Weill Medical College of Cornell University. The trial plans to enroll 500 participants.